Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.

Cascinu S, Fedeli A, Fedeli SL, Catalano G

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Jan 1993Cited by 54 (Europe PMC)

PMID8418225DOI10.1200/jco.1993.11.1.148PepBankPUB-08418225

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In chemotherapy-induced diarrhea, resolution occurred in 19 octreotide patients versus three loperamide patients (P < .005).
In plain wordsIn chemotherapy-induced diarrhea, diarrhea resolved in 19 octreotide patients versus three loperamide patients.
Peptide
Octreotide
Outcome
IncreaseDiarrhea resolution
Study
n = 41
Comparator
Loperamide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.1 mg twice per day · subcutaneous · 3 daysAs given in this study (human).
Measurements
Patients with diarrhea resolved
19 patients
octreotide arm
Patients with diarrhea resolved
3 patients
loperamide arm, all after the third day
Resolution within first day
1 patients
octreotide
Resolution within second day
4 patients
octreotide
Resolution within third day
14 patients
octreotide
Source sentences
Summary
Diarrhea resolved in 19 patients in the octreotide arm (one within the first day; four within the second day; and 14 within the third day) versus only three (all after the third day of therapy) in the loperamide arm (P < .005).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
Summary · context
Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
Report a problemFND-0841822501
02HumanRandomized controlled trialEfficacy outcome
In chemotherapy-induced diarrhea, first-day median stool frequency was four with octreotide versus five with loperamide.
In plain wordsIn chemotherapy-induced diarrhea, first-day median stool frequency was four with octreotide versus five with loperamide.
Peptide
Octreotide
Outcome
DecreaseMedian stool frequency on first day
Study
n = 41
Comparator
Loperamide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.1 mg twice per day · subcutaneous · 3 daysAs given in this study (human).
Measurements
Median stool frequency on first day
4 stools
octreotide arm
Median stool frequency on first day
5 stools
loperamide arm
Source sentences
Summary
Median frequency of stools in the 3 days of therapy was four, three, and zero in the octreotide arm and five, five, and five in the loperamide arm.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
Summary · context
Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
Report a problemFND-0841822502
03HumanRandomized controlled trialEfficacy outcome
In chemotherapy-induced diarrhea, second-day median stool frequency was three with octreotide versus five with loperamide.
In plain wordsIn chemotherapy-induced diarrhea, second-day median stool frequency was three with octreotide versus five with loperamide.
Peptide
Octreotide
Outcome
DecreaseMedian stool frequency on second day
Study
n = 41
Comparator
Loperamide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.1 mg twice per day · subcutaneous · 3 daysAs given in this study (human).
Measurements
Median stool frequency on second day
3 stools
octreotide arm
Median stool frequency on second day
5 stools
loperamide arm
Source sentences
Summary
Median frequency of stools in the 3 days of therapy was four, three, and zero in the octreotide arm and five, five, and five in the loperamide arm.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
Summary · context
Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
Report a problemFND-0841822503
04HumanRandomized controlled trialEfficacy outcome
In chemotherapy-induced diarrhea, third-day median stool frequency was zero with octreotide versus five with loperamide.
In plain wordsIn chemotherapy-induced diarrhea, third-day median stool frequency was zero with octreotide versus five with loperamide.
Peptide
Octreotide
Outcome
DecreaseMedian stool frequency on third day
Study
n = 41
Comparator
Loperamide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.1 mg twice per day · subcutaneous · 3 daysAs given in this study (human).
Measurements
Median stool frequency on third day
0 stools
octreotide arm
Median stool frequency on third day
5 stools
loperamide arm
Source sentences
Summary
Median frequency of stools in the 3 days of therapy was four, three, and zero in the octreotide arm and five, five, and five in the loperamide arm.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
Summary · context
Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
Report a problemFND-0841822504
05HumanRandomized controlled trialSafety outcome
In chemotherapy-induced diarrhea, neither octreotide nor loperamide produced observed side effects.
In plain wordsIn chemotherapy-induced diarrhea, no side effects were observed with octreotide or loperamide.
Peptide
Octreotide
Outcome
No significant changeSide effects
Study
n = 41
Comparator
Loperamide
Outcome group
Adverse events · Gastrointestinal
Studied dose
0.1 mg twice per day · subcutaneous · 3 daysAs given in this study (human).
Source sentences
Summary
No side effects were observed in both arms.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
Summary · context
Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
Report a problemFND-0841822505
06HumanRandomized controlled trialEfficacy outcome
In chemotherapy-induced diarrhea, one octreotide patient versus ten loperamide patients required hospitalization for parenteral fluids and electrolytes.
In plain wordsIn chemotherapy-induced diarrhea, one octreotide patient versus ten loperamide patients needed hospitalization for fluids and electrolytes.
Peptide
Octreotide
Outcome
DecreaseHospitalization for fluids and electrolytes
Study
n = 41
Comparator
Loperamide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
0.1 mg twice per day · subcutaneous · 3 daysAs given in this study (human).
Measurements
Patients hospitalized for fluids and electrolytes
1 patients
octreotide arm
Patients hospitalized for fluids and electrolytes
10 patients
loperamide arm
Source sentences
Summary
Ten patients on the loperamide arm and only one on the octreotide arm required hospitalization for parenteral replenishment of fluids and electrolytes.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized trial that compared octreotide with loperamide, the drug most commonly used for therapy for this disorder.
Summary · context
Twenty-one patients received octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days, and 20 patients received loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days.
Report a problemFND-0841822506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.